Michael Men, M.D.
Chief Executive Officer and Chairman
Co-founder, chief executive officer, and chairman. He has overseen company operations since founding and led the team that advanced IMS001 to FDA IND clearance in 2020.
People
Leadership, board, and scientific advisors
The people responsible for translating T-MSC biology into a clinical-stage company.
Leadership team
Operating leadership of ImStem Biotechnology.
Xiaofang Wang, M.D., Ph.D.
Chief Technology Officer
Co-founder and CTO. Key inventor of the two-step hESC-to-T-MSC method. Trained at Peking University, MD Anderson, Yale, and UConn Stem Cell Institute.
Board of directors
Governance of the company.
Michael Men, M.D.
Chairman of the Board · CEO
Co-founder and chairman since inception, with responsibility for major company decisions and the clinical translation of IMS001.
Xiaofang Wang, M.D., Ph.D.
Director · CTO
Co-founder and director. Leads technology strategy, quality, and manufacturing development for the T-MSC platform.
Scientific advisors
Independent scientific counsel across stem-cell biology, MS, rare disease, and genome editing.
Rudolf Jaenisch, M.D., Ph.D.
Scientific advisor
Professor of Biology at MIT and founding member of the Whitehead Institute. Pioneer of transgenic science and a major figure in embryonic and induced pluripotent stem cells.
Jeffery Cohen, M.D.
Scientific advisor
Director of the Mellen Center for Multiple Sclerosis at Cleveland Clinic. Designed and conducted major MS trials, including work that led to fingolimod and an autologous MSC study in progressive MS.
Hongkui Deng, Ph.D.
Scientific advisor
Director of the Peking University Stem Cell Research Center. Known for chemical reprogramming of adult cells and CRISPR-based hematopoietic gene editing.
Troy Lund, M.D., Ph.D.
Scientific advisor
Pediatric transplant physician at the University of Minnesota, specializing in adrenoleukodystrophy and collaborating with ImStem on T-MSC for cALD.
Joel Pachter, Ph.D.
Scientific advisor
Professor of Cell Biology at UConn Health. Expert in blood–brain barrier biology and collaborator on T-MSC mechanism in multiple sclerosis.
David Benjamin Turitz Cox, M.D., Ph.D.
Scientific advisor
Physician-scientist trained in the Zhang lab at MIT; advisor on genome-editing tools and their application to cell therapy.
Renhe Xu, M.D., Ph.D.
Founder · Scientific advisor
Founder of ImStem. Associate Dean of the Faculty of Health Sciences at the University of Macau; formerly Director of the UConn Stem Cell Institute.